| Literature DB >> 34835962 |
Anna Gawron-Gzella1, Justyna Chanaj-Kaczmarek1, Judyta Cielecka-Piontek1.
Abstract
Bearing in mind the growing interest in Yerba Mate, a comprehensive study has been prepared containing the most important aspects and possibilities of its use. The introduction of the work contains the species characteristics of Yerba Mate, as well as information about the origin and places of cultivation. The next part focuses on the analysis of the composition, pointing to purine alkaloids, polyphenols, saponins, and minerals as groups of active compounds responsible for the clinical activity of Yerba Mate. The review of the results of preclinical and clinical studies indicates activity in relation to the stimulating effect, reducing weight by stimulating lipolysis, cardioprotective, anti-diabetic, and anti-inflammatory effects. The information about the action of Yerba Mate is supplemented by the characteristics of its potential toxicity in terms of PAHs content (in particular benzo[α]pyrene) and preparation as a determinant of increased irritation. The current data on the effects of Yerba Mate and the wide safety margin of its use position this raw material as a valuable component of functional food. The growing frequency of consuming Yerba Mate, conditioned by the availability resulting from the globalization of the market and the information provided about it's the pro-health effects, will position Yerba Mate's popularity among wider population groups.Entities:
Keywords: Yerba Mate; active compounds; biological activity; functional food; potential toxicity
Mesh:
Substances:
Year: 2021 PMID: 34835962 PMCID: PMC8622869 DOI: 10.3390/nu13113706
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Purine alkaloids and polyphenols content in Yerba Mate infusions.
| Preparation of Yerba Mate Infusions | Repeats | Content (mg/100 mL Infusion) | ||
|---|---|---|---|---|
| Purine Alkaloids | ||||
| Caffeine | Theobromine | |||
| De Morais et al. [ | 50 mg of green or 20 mg of roasted Yerba Mate/1 mL of boiling water, infused for 10 min | 1st | 15.74 | 4.81 |
| 10.99 | 2.70 | |||
| respectively | respectively | |||
| Meinhart et al. [ | 1st | 13.7–26.4 | 2.8–6.4 | |
| 2nd | 6.5–19.0 | 1.7–4.4 | ||
| 3rd | 2.3–13.6 | 0.6–3.1 | ||
| 4th | 1.6–11.6 | 0.4–2.9 | ||
| 10th | 1.0–7.3 | 0.3–1.6 | ||
| 18th | 1.3–5.7 | 0.3–1.3 | ||
| 30th | 1.5–6.6 | 0.3–1.6 | ||
| 1st | 35.8 | 8.2 | ||
| 2nd | 56.5 | 12.3 | ||
| 3rd | 48.2 | 10.4 | ||
| 4th | 33.2 | 7.0 | ||
| 10th | 12.2 | 2.4 | ||
| 18th | 6.1 | 1.1 | ||
| 30th | 2.9 | 0.5 | ||
| Kruszewski et al. [ | 3.5 g Yerba Mate brewed with 100 mL water at 70 °C for: | 1st | - | |
| 15 min | 15.0 | |||
| 30 min | 17.5 | |||
| 45 min | 25.5 | |||
| 60 min | 25.8 | |||
| 3.5 g Yerba Mate infused with 100 mL boiling water for: | 1st | - | ||
| 15 min | 11.8 | |||
| 30 min | 12.3 | |||
| 45 min | 13.1 | |||
| 60 min | 15.8 | |||
|
| ||||
| Bastos et al. [ | 5 g of green or roasted Yerba Mate were extracted continuously for 4 h in a Soxhlet apparatus with 100 mL of water at 97 °C | 1st | 733 and 671 *, respectively | |
| De Morais et al. [ | 50 mg of green or 20 mg of roasted Yerba Mate/1 mL of boiling water, infused for 10 min | 1st | 551 and 174 **, respectively | |
| De Mejía et al. [ | 2.7 g of traditional Yerba Mates brewed with 250 mL of boiling water for 10 min | 1st | 130–260 * | |
| Meinhart et al. [ | 1st | 120.5–235.6 | ||
| 2nd | 55.5–121.1 | |||
| 3rd | 21.9–104.3 | |||
| 4th | 12.3–62.9 | |||
| 10th | 11.0–31.4 | |||
| 18th | 12.8–29.2 | |||
| 30th | 14.5–38.6 * | |||
| 1st | 235.3 | |||
| 2nd | 350.0 | |||
| 3rd | 268.4 | |||
| 4th | 208.5 | |||
| 10th | 72.3 | |||
| 18th | 36.3 | |||
| 30th | 19.7 * | |||
| Colpo et al. [ | 85 g Yerba Mates (Argentinean, Brazilian and Uruguayan brands) brewed with 70 mL water at 85 °C for 1 min | 1st | 408–1185 | |
| 2nd | 220–1451 | |||
| 5th | 97–1233 | |||
| 10th | 72–761 | |||
| 15th | 56–514 * | |||
* the content expressed as gallic acid equivalent (mg GAE/100 mL infusion), ** the content expressed as chlorogenic acid equivalent (mg CGA/100 mL infusion).